Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
New GSK Investor update
Emma Walmsley, CEO, and other members of CET will host a virtual investor update at 14:00-17:30 BST on Wednesday 23 June. The update will provide a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.
Latest information
Latest press releases
- ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
- GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
- GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
Annual Report 2020
We published our Annual Report 2020 on 09 March 2021. View the summary and download the full report or individual sections.
Sign up for announcements
Sign up to receive email notifications when we publish a stock exchange announcement.